Navigation Links
Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
Date:10/20/2008

ancer therapeutics company and a cancer diagnostics company. Lixte was created to capitalize on opportunities to develop low cost, specific and sensitive tests for the early detection of cancers. Over the past two years, however, the Company has evolved into what is now primarily a cancer drug discovery company, using biomarker technology to develop new potentially more effective anti-cancer drugs.

The Company is developing new treatments for several cancers for which better treatments are urgently needed. The primary focus is on the most common and most aggressive type of brain cancer of adults, glioblastoma multiforme ("GBM"). The research on brain tumors is being conducted with the National Institute of Neurological Disorders and Stroke ("NINDS") of the National Institutes of Health ("NIH") under a Cooperative Research and Development Agreement ("CRADA").

The Company has expanded the scope of its program to other cancers of neural tissue (nerve and brain), including medulloblastoma, the most common brain tumor of children, and neuroblastoma, the most common cancer of children, and to other common cancers of adults. The program was expanded because each of two distinct types of drugs being developed by Lixte inhibits the growth of cell lines of GBM, medulloblastoma, neuroblastoma, and pancreatic cancer in animal models of these diseases and is also active against breast, colon, lung, prostate, ovary, stomach and liver cancer and the major types of leukemias in cell culture.

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors
'/>"/>

SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
2. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
3. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
4. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
5. SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies
6. Vineland Welcomes Dr. Daryl Somers as Research Chair, Molecular Breeding and Biotechnology
7. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
8. Monsanto Recognized as Top Biotechnology Employer by Science Magazine
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
11. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2010)... Stock Exchange Symbol: MS , ... , , ... ... EDMONTON , March 16 ... ...
(Date:3/16/2010)... PharmAthene, Inc. (Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial results ... ... , ... ... ...
(Date:3/16/2010)... March 16 The Gynecologic Cancer Foundation (GCF) and the Claudia ... as the first recipient of the $50,000 GCF/Claudia Cohen Prize for Outstanding ... (SGO) 41st Annual Meeting on Women,s Cancer, meeting in San Francisco ... ... ...
(Date:3/16/2010)... (LSE: SHP,NASDAQ; SHPGY), announces that it has received a Paragraph IV Notice ... New Drug Application ("ANDA") for a generic version of Shire,s 1,mg, 2mg, ... ... ... , ...
Breaking Biology Technology:BioMS Medical Announces 2009 Year End Results 2BioMS Medical Announces 2009 Year End Results 3BioMS Medical Announces 2009 Year End Results 4BioMS Medical Announces 2009 Year End Results 5BioMS Medical Announces 2009 Year End Results 6BioMS Medical Announces 2009 Year End Results 7BioMS Medical Announces 2009 Year End Results 8BioMS Medical Announces 2009 Year End Results 9BioMS Medical Announces 2009 Year End Results 10PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 2PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 2Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 3Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 4Paul Goodfellow, PhD, Awarded First GCF/Claudia Cohen Prize for Outstanding Gynecologic Cancer Researcher 5Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 2Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 3Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals 4
... 9 The International Center for Adult,Stem ... that,it has officially launched a global communications ... Spinal Cord Injury Symposium,Olfactory Mucosa Autografts (OMA) ... through May 10th in Argostolli, Kefalonia, Greece. ...
... Calif., May 9 InterMune, Inc.,(Nasdaq: ITMN ) ... of InterMune, will present at the Bank of America ... 2008 at 9:20 a.m. PDT (12:20,p.m EDT)., To ... and other,interested parties may log on to the investor ...
... Medical,Innovations (Amex: IMA ) today announced ... Inc. was successfully completed and,effective prior to ... 2008. Matria,headquartered in Marietta, Georgia, provides comprehensive, ... of women,s and,children,s health, cardiology and oncology. ...
Other Biology Technology:International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece 2Inverness Medical Innovations Completes Acquisition of Matria Healthcare, Inc. 2
(Date:3/18/2010)... can live for twenty years, fertilizing millions of eggs ... activity. , Danish researchers who have studied ants ... 1992 discovered that in both ant and bee species ... fluid favors the survival of its own sperm over ... stored, leafcutter ant queens neutralize male-male sperm competition with ...
(Date:3/18/2010)... available in Spanish . , Feeding ... as part of their regular diet makes them ... a study by Agricultural Research Service (ARS) scientists ... and overall behavioral activity among young female pigs ... acquired through diet, is the precursor for the ...
(Date:3/18/2010)... Biotech, Inc., ( www.genwaybio.com ) the US-based diagnostic company ... is expanding this cancer testing program internationally. An ... YouTM Cancer Assessment in Greece starting in April. ... as well. GenWay currently offers this test in ... Sergey Sikora, Vice President of Business Development, said, "The ...
Breaking Biology News(10 mins):Females shut down male-male sperm competition in leafcutter ants 2Tryptophan-enriched diet reduces pig aggression 2Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 1Moravia Worldwide Names George Krawczyk as Sales Director for Ireland and UK 61905 2Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 1Barbara Fentress Designer of the Denver International Airport and Convention Center Offers Her Private Mansion at Absolute Auction 61902 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 1Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 2Ophthalmic Equipment Distributor Latham 26amp 3B Phillips SE Division Unveils Website 61899 3
... 2008 Simplifying the process for forming compounds that ... pharmaceuticals and plastics, has earned one University of Houston ... assistant professor of chemistry in the College of Natural ... young scientists, mathematicians and economists in the United States ...
... UK scientist has discovered clumps of previously-unreported callus hairs ... and closely-related varieties, which may have storage implications for ... apples is really exciting, says Dr Mary Parker of ... for about as long as human history and Fuji ...
... as productive as conventional systems" The answer is an ... Yes most of the time for corn and soybeans ... of Wisconsin-Madison and agricultural consulting firm AGSTAT in the ... based their answer on results from the Wisconsin Integrated ...
Other Biology News:Simplifying manufacture of drugs, plastics earns UH chemist top honor 2Popular apple variety harbors unusual cell growth 2Are organic crops as productive as conventional? 2
... VARIOMAG Magnetic Stirrers operate without any moving ... bearings, making VARIOMAG Magnetic Stirrers 100% wear-free ... drive can be hermetically sealed, making it ... is why VARIOMAG Magnetic Stirrers are particularly ...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
...
... a-Amylase is an enzyme that ... mixture of maltose, maltotriose, and dextrins. ... of the human body is of,clinical ... states including,pancreatitis and diabetes; plant and ...
Biology Products: